LGND logo

LIGAND PHARMACEUTICALS

LGNDNASDAQ
๐Ÿ† #1101 by market capEarnings Oct 29 ยท PreUS Equity
$318.78โ–ฒ $7.05 (+2.26%)
Market closed ยท at close
๐Ÿ””
Track LGND
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 2.3%
7dโ–ฒ 3.6%
14dโ–ฒ 6.7%
30dโ–ฒ 2.8%
ytdโ–ฒ 68.6%
1yโ–ฒ 72.2%
๐ŸฆMarket Cap
$6.36B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
54.9%
High Growth
๐Ÿ“ŠGross Margin
95.4%
High
๐Ÿ’ตFCF Margin
46.2%
Strong
โš–๏ธP/S Ratio
21.3x
Expensive
Otter Score
68
Fair

Trading Snapshot

Day Range
$309.69 โ€“ $319.59
52-Week Range
$175.89 โ€“ $326.63
Volume (shares)
268,343
Avg Volume (shares)
โ€”
Shares Outstanding
19.9M
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
$268M
Last Q Revenue
$64M
P/E Ratio
31.4
P/S Ratio
21.3x
EPS (TTM)
$9.40
Dividend Yield
โ€”
Dilution (1yr)
+11.4%
LGND logo

LIGAND PHARMACEUTICALS

LGND
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$268Mโ–ฒ +60.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.5%โ–ฒ +4.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
$47Mโ–ผ โˆ’308.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$49Mโ–ผ โˆ’36.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
21.1Mโ–ฒ +11.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
โˆ’$277Mโ–ผ โˆ’$342M YoY
StockOtter ยท stockotter.space

About LIGAND PHARMACEUTICALS

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The companyโ€™s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
68/100

Analyst Ratings

โ“˜
Consensus
Buy
17 analysts
Strong Buy7
Buy9
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

GlobeNewsWireยท1d ago

Ligand to Participate in November Investor Conferences

JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: UBS Glo

GlobeNewsWireยท6d ago

Ligand to Host Investor Day on December 8, 2026

JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m.

GlobeNewsWireยท13d ago

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026.

GlobeNewsWireยทSep 24

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell

Business WireยทSep 22

Sydnexis Announces Royalty Agreement with Ligand for Ryjuneaยฎ

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Lig

PRNewsWireยทSep 22

Primrose Bioยฎ Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Hea